<DOC>
	<DOCNO>NCT00448214</DOCNO>
	<brief_summary>To evaluate safety tolerability YM150 subject non-valvular atrial fibrillation ( NVAF ) obtain information pharmacokinetics pharmacodynamics ( anti-thrombotic potential ) target population</brief_summary>
	<brief_title>Direct Factor Xa Inhibitor YM150 Prevention Stroke Subjects With Non-Valvular Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Darexaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Subjects eligible study follow apply : Subject paroxysmal permanent persistent NVAF Subject INR 2.0 aPTT â‰¤ 1.5 time upper limit normal baseline visit . Legal minimum age requirement ( countryspecific ) . Written inform consent obtain . History heart valve disorder History rheumatic fever . History stroke and/or systemic embolism ( include TIA ) . History Acute Coronary Syndrome ( ACS ) . Indication warfarin NVAF . Known hemorrhagic disorder and/or coagulation disorder . Active bleed condition associate increase risk bleeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Factor Xa inhibitor</keyword>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Stroke</keyword>
	<keyword>Ischemic attack</keyword>
	<keyword>thromboembolism</keyword>
	<keyword>Prevention control</keyword>
</DOC>